GlassScriptPhysician profile
Camille Licata
NPI 1477980415
$1,978.67
in general payments reported to CMS, 2019-2025
15 companies · $641 in 2025
The $641 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.74 · 2022: $39.63 · 2023: $431 · 2024: $826 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $303.07 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $255.07 | 2024-2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $250.76 | 2024-2025 | Stelara, Tremfya |
| Genzyme Corporation | $239.83 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $217.91 | 2023-2025 | Cobenfy, Zeposia |
| Novo Nordisk INC | $117.76 | 2025 | Wegovy |
| Abbvie INC. | $113.12 | 2022-2024 | |
| Lilly USA, LLC | $113.04 | 2024 | Omvoh |
| Ardelyx, INC. | $108.70 | 2022-2023 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $94.55 | 2023 | Lokelma |
| Ipsen Biopharmaceuticals, INC | $91.80 | 2024 | Iqirvo |
| Daiichi Sankyo INC. | $31.32 | 2022-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $16.13 | 2021 | |
| Merck Sharp & Dohme LLC | $13.23 | 2021 | |
| Amgen INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Licata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.